

Active substances set

Search phrase: daunorubicin / cytarabine

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute myeloid leukemia

**Daunorubicin /
cytarabine**

Daunorubicin / Cytarabine is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).



**FULL
REIMBURSEMENT**



ESMO